Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomarkers, Communications Are Key To Accelerating R&D, FDA Says

Executive Summary

Genentech's Herceptin is a good example of how the tradeoffs in targeted drug development can work out medically and commercially, FDA Commissioner McClellan told an IBC meeting in Boston Aug. 12
Advertisement

Related Content

Abbott Rx For R&D Includes Tandem Drug/Biologic Development
Abbott Rx For R&D Includes Tandem Drug/Biologic Development
Abbott Rx For R&D Includes Tandem Drug/Biologic Development
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA Genomics Policy: Data Will Be Used In Reviews Only By Sponsor Consent
Advertisement
UsernamePublicRestriction

Register

PS042310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel